Filtered By:
Condition: Hemorrhagic Stroke
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 553 results found since Jan 2013.

Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study)
Abstract The safety and efficacy of non-vitamin K oral anticoagulant (NOAC) compared with warfarin in treating patients with non-valvular atrial fibrillation (NVAF) who developed acute ischemic stroke or transient ischemic attack (AIS/TIA), particularly those receiving tissue-plasminogen activator (tPA) therapy, remains unclear. Between April 2012 and December 2014, we conducted a multicenter prospective cohort study to assess the current clinical practice for treating such patients. We divided the patients into two groups according to the administration of oral anticoagulants (warfarin or NOACs) and tPA therapy. ...
Source: Journal of Thrombosis and Thrombolysis - May 19, 2016 Category: Hematology Source Type: research

CHADS2 risk score and rate of stroke or systemic embolism and major bleeding in patients with non-valvular atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants.
Authors: VAN Mieghem W, Lancellotti P Abstract Randomized trials showed non-inferior or superior results of the non-vitamin K antagonist oral anticoagulants (NOACs) compared with warfarin in patients with non-valvular atrial fibrillation (AF). Despite the absence of direct head-to-head comparisons between the different NOACs, certain molecules have been proposed for subgroups of patients based mainly on the perception of different bleeding risks. The CHADS2 score has been uniformly used in the inclusion criteria of these studies and shared similar risk factors as the haemorrhagic risk score HAS-BLED. The aim of the...
Source: Acta Cardiologica - July 8, 2017 Category: Cardiology Tags: Acta Cardiol Source Type: research

Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
CONCLUSION: The PAROS study will provide real-life data on the characteristics of NVAF patients and their anticoagulant prescription in France. PMID: 29191525 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 27, 2017 Category: Cardiology Authors: Picard F, Ducrocq G, Danchin N, Falissard B, Hanon O, Mahe I, Touzé E, Steg PG Tags: Arch Cardiovasc Dis Source Type: research

Low cholesterol may increase risk for hemorrhagic stroke
LDL cholesterol levels below 70 mg/dL linked to higher risk of haemorrhagic stroke Related items fromOnMedica NICE issues guidelines on neurological conditions Stroke patients still not getting care they need Vitamin D supplements do not confer cardiovascular protection Physical activity might offset harms of time spent sitting Recurrent stroke more likely at very low BP
Source: OnMedica Latest News - July 2, 2019 Category: UK Health Source Type: news

Low cholesterol may increase risk for haemorrhagic stroke
LDL cholesterol levels below 70 mg/dL linked to higher risk of haemorrhagic stroke Related items fromOnMedica NICE issues guidelines on neurological conditions Stroke patients still not getting care they need Vitamin D supplements do not confer cardiovascular protection Physical activity might offset harms of time spent sitting Recurrent stroke more likely at very low BP
Source: OnMedica Latest News - July 2, 2019 Category: UK Health Source Type: news

Cost-effectiveness of dabigatran compared with rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation in China.
Abstract PURPOSE: In China, dabigatran and rivaroxaban are the only approved non-vitamin K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this article was to assess the cost-effectiveness of dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in Chinese patients with AF from the perspective of the Chinese health care system. METHODS: A Markov model was constructed to estimate the cost-effectiveness of dabigatran versus rivaroxaban. Clinical events were modeled for a lifetime horizon, based on clinical efficacy data from indirect treatment...
Source: Clinical Therapeutics - January 9, 2020 Category: Drugs & Pharmacology Authors: Dong SJ, Wu B, Zhai SD, Zhang YJ, Chu YB, Gupta P, Li YH Tags: Clin Ther Source Type: research

Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients.
CONCLUSION: In patients with AF and an increased risk of stroke, prophylaxis with apixaban was highly cost-effective from the perspective of the Austrian health care system. PMID: 32700584 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - July 24, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Endovascular stroke treatment in orally anticoagulated patients: an analysis from the German Stroke Registry-Endovascular Treatment
ConclusionsET can be performed safely and successfully in LVO stroke patients treated with OAC.Clinical trial registration-URLhttp://www.clinicaltrials.gov. Unique identifier: NCT03356392.
Source: Journal of Neurology - December 29, 2020 Category: Neurology Source Type: research

Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis
ConclusionBased on current evidence, for stroke prevention and treatment in patients with AF, the most safe DOAC is edoxaban in terms of fatal bleeding; dabigatran in terms of major bleeding and intracranial hemorrhage and apixaban in terms of gastrointestinal bleeding. However, given the nature of indirect comparisons, more high-quality evidence from head-to-head comparisons is still needed to confirm them.
Source: Cardiovascular Drugs and Therapy - August 26, 2021 Category: Cardiology Source Type: research

Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants
We report a case of an ischemic stroke after a successful catheter ablation of atrial fibrillation (AF) and continuous oral anticoagulation therapy with direct oral anticoagulants (DOACs), which was the trigger for diagnosing antiphospholipid syndrome (APS). A 68-year-old woman underwent catheter ablation of persistent AF and continued oral anticoagulation with edoxaban at a dose of 30 mg once daily after the ablation procedure. An asymptomatic intracerebral hemorrhage was detected by brain computed tomography and magnetic resonance imaging one month post-ablation. Oral anticoagulation with dabigatran at 110 mg twice daily...
Source: International Heart Journal - January 31, 2022 Category: Cardiology Authors: Yumiko Haraguchi Kohki Nakamura Mitsuho Inoue Takehito Sasaki Kentaro Minami Shingo Yoshimura Shigeto Naito Source Type: research